ILDR2 Antibody
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-09736
Key Product Details
Species Reactivity
Human
Applications
Western Blot
Label
Unconjugated
Antibody Source
Polyclonal Rabbit
Concentration
0.5 mg/ml
Product Specifications
Immunogen
The immunogen is a synthetic peptide directed towards the C-terminal region of human ILDR2 (NP_955383.1). Peptide sequence QDDQEDASDDALPPYSELELTRGPSYRGRDLPYHSNSEKKRKKEPAKKTN
Clonality
Polyclonal
Host
Rabbit
Theoretical MW
56 kDa.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Scientific Data Images for ILDR2 Antibody
Western Blot: ILDR2 Antibody [NBP3-09736]
Western Blot: ILDR2 Antibody [NBP3-09736] - Western blot analysis of ILDR2 in Human 721_B Whole Cell. Antibody dilution at 1ug/mlApplications for ILDR2 Antibody
Application
Recommended Usage
Western Blot
1.0 ug/ml
Formulation, Preparation, and Storage
Purification
Affinity purified
Formulation
PBS, 2% Sucrose
Preservative
0.09% Sodium Azide
Concentration
0.5 mg/ml
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Background: ILDR2
Long Name
Immunoglobulin Like Domain Containing Receptor 2
Alternate Names
Angulin-3, C1orf32, Dbsm1, DJ782G3.1, LISCH-Like
Gene Symbol
ILDR2
Additional ILDR2 Products
Product Specific Notices for ILDR2 Antibody
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...